TOP > 外国特許検索 > RAPIDLY PROGRESSIVE SPORADIC ALS TEST METHOD, TEST KIT, AND DRUG SCREENING METHOD

RAPIDLY PROGRESSIVE SPORADIC ALS TEST METHOD, TEST KIT, AND DRUG SCREENING METHOD コモンズ

外国特許コード F160008735
整理番号 NU-653
掲載日 2016年4月28日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP057071
国際公開番号 WO 2016147942
国際出願日 平成28年3月8日(2016.3.8)
国際公開日 平成28年9月22日(2016.9.22)
優先権データ
  • 特願2015-051093 (2015.3.13) JP
発明の名称 (英語) RAPIDLY PROGRESSIVE SPORADIC ALS TEST METHOD, TEST KIT, AND DRUG SCREENING METHOD コモンズ
発明の概要(英語) The present invention addresses the problem of developing a therapeutic drug and treatment method for suppressing the advance of ALS by elucidating the condition and etiology of the disease, especially in sporadic ALS patients. Sporadic ALS patients were classified as four types on the basis of the advance of the condition after onset. Genome-wide association analysis was conducted, and seven SNPs related to the rapidly progressive type that exacerbates rapidly, among the four types, were discovered. It also became apparent that the SNPs are related to titin expression. The SNPs and titin expression can serve as markers of rapidly progressive ALS, and therapeutic and prophylactic methods for suppressing the condition can be developed using these markers.
特許請求の範囲(英語) [claim1]
1. Being the method of inspecting the similar type of advance after the emerging of the ALS patient,
Reference SNP ID number of ALS patient: rs12052983, rs23114582, rs2303537, rs4894020, rs6453709, rs600176 and rs957875 in each case one one base multi types are inspected at least,
The inspection method of featuring that it decides that risk of quick advance type is high when the aforementioned one base multi types are [mainaareru].
[claim2]
2. Being the method of inspecting the similar type of advance after the emerging of the ALS patient,
The revelation quantity of [chichin] of the ALS patient is measured,
When the [chichin] revelation quantity is lower than threshold, the inspection method of featuring that it decides that the risk which is advanced to quick advance type is high.
[claim3]
3. Being the method of inspecting the similar type of advance after the emerging of the ALS patient of the statement in claim 2,
As for the revelation quantity of aforementioned [chichin], mRNA and/or the inspection method of featuring that the protein revelation quantity is measured.
[claim4]
4. Being the method of inspecting the similar type of advance after the emerging of the ALS patient of the statement in claim 3,
As for the aforementioned [chichin] revelation quantity the inspection method of featuring that mRNA revelation is measured with quantitative PCR.
[claim5]
5. Being the method of inspecting the similar type of advance after the emerging of the ALS patient of the statement in claim 3,
As for the revelation quantity of aforementioned [chichin] the inspection method of featuring that protein revelation is measured due to the anti- [chichin] antibody.
[claim6]
6. Claim 1-5 in each case being the method of inspecting the similar type of advance after the emerging of the ALS patient of 1 section statements,
The inspection method of featuring that you inspect making use of the lymphocyte which is obtained from the patient.
[claim7]
7. Being the kit which is inspected whether the ALS patient is classified into quick advance type ALS,
Reference SNP ID number: At least either rs12052983, rs23114582, rs2303537, rs4894020, rs6453709, rs600176 or rs957875 the PCR primer in order to detect one one base multi types and the quantitative PCR primer in order to analyze the [chichin] revelation quantity, the [chichin] revelation quantity at least either of the antibodies in order to measure the inspection kit which features that one is included.
[claim8]
8. Being the method the screening of doing the medicine which controls the advance of quick advance type ALS,
The suffering *** substance is made to contact the cultured cell,
The screening method of featuring that it selects the increase of the [chichin] revelation quantity as index.
[claim9]
9. Being the method the screening of doing the medicine which controls the advance of quick advance type ALS of statement in claim 8,
The aforementioned cultured cell reference SNP ID number: The screening method of featuring that rs12052983, rs23114582, rs2303537, rs4894020, rs6453709, rs600176 and rs957875 are [mainahomoareru].
[claim10]
10. Being screening method of statement in claim 8 or 9,
The screening method of featuring that they are the lymphocyte cell stocks which the above-mentioned cultured cell establishes from the peripheral blood of the quick advance type ALS patient.
[claim11]
11. Claim 8-10 in each case being screening method of 1 section statements,
As for the aforementioned [chichin] revelation, mRNA and/or the screening method of featuring that due to measuring the protein.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGOYA UNIVERSITY
  • 発明者(英語)
  • SOBUE GEN
  • ATSUTA NAOKI
  • WATANABE HAZUKI
  • HIRAKAWA AKIHIRO
  • NAKATOCHI MASAHIRO
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
名古屋大学の公開特許情報を掲載しています。ご関心のある案件がございましたら、下記まで電子メールでご連絡ください。

PAGE TOP

close
close
close
close
close
close